P/E của cổ phiếu ZVRA là bao nhiêu?

Zevra Therapeutics Inc. (ZVRA) hiện giao dịch ở mức P/E 4.76 lần.

ROE của cổ phiếu ZVRA là bao nhiêu?

Zevra Therapeutics Inc. có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 60.36%.

Tỷ suất cổ tức của ZVRA là bao nhiêu?

Zevra Therapeutics Inc. có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của ZVRA là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của ZVRA ở mức 77/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu ZVRA không?

Điểm AI Timing của ZVRA là 28/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu ZVRA thuộc ngành nào?

Zevra Therapeutics Inc. được xếp vào ngành Healthcare >> Biotechnology trên sàn NASDAQ

Cổ phiếu ZVRA (NASDAQ) | ZEVRA THERAPEUTICS INC.

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

ZVRA AI Analysis Summary

Our AI summary for ZVRA: Zevra Therapeutics Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 4.76, ROE of 60.36%, a dividend yield of 0.00%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ZVRA

Zevra Therapeutics Inc.

US:NASDAQ STOCK Healthcare >> Biotechnology News 97

USD 10.52

0.47 (4.62%) Day Change

Watchlist Portfolio Compare Chart

4.76

P/E

0.00

D/E

60.4%

ROE

44.6%

ROA

0.00%

Div Yield

-0.69

PEG

ZEVRA THERAPEUTICS INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 10.52 Price 0.47 (4.62%) Day Change	NEWS SCORE: 97

ZVRA Chất lượng tổng thể của cố phiếu Tốt ( Chất lượng = 77) nhưng Thời điểm mua ...(Sign In to See)...

Loading chart...

77 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Good

Reason: Lịch sử ROE tương đối thấp
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Khá , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...

Yếu tố Chất lượng

66%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	97
Magic Formula Rank by ROA	63 GOOD
Magic Formula Rank by ROE	63 GOOD
Magic Formula Rank by ROIC	76 GOOD
Price	10.52
PBV / Sector	2.89 / 44,022.72
Earning Per Share	2.20

PE / Sector	4.76 / 19.17 GREAT
PEG or PE/Growth / Sector	-0.69 / 1.24
Average 1M Daily Value	17.89 M GREAT
Average 1W Daily Value	13.64 M GREAT

Yếu tố Kỹ thuật

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

66%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	101.58 / 98.24 GREAT
NPM Average (%) / Sector	-139.65 / -1,697.63
NPM Change Average (%) / Sector	10.64 / 5,097.97 GOOD
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	44.59 / 185,260.96 GREAT
ROA Average (%) / Sector	-7.07 / 36,684.70
ROA Change Average (%) / Sector	10.00 / 422,221.66 GOOD
ROE (%) / Sector	60.36 / 243,762.23 GREAT
ROE Average (%) / Sector	-52.38 / 48,758.47
ROE Change Average (%) / Sector	64.53 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Chi tiết đăng ký

Analyze Date	2026-08-05 08:01:08
Symbol	ZVRA
Name	ZEVRA THERAPEUTICS INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	59.12 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	594.40 / 9,586.08

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 101 Federal Street, Boston, MA, United States, 02110

Phone: 888 958 1253

Website: https://www.zevra.com

Employees: 61

Sector: Healthcare >> Biotechnology

Description: Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.